ARCT
Price
$9.49
Change
-$1.54 (-13.96%)
Updated
Nov 2 closing price
Capitalization
269.73M
2 days until earnings call
Intraday BUY SELL Signals
BCYC
Price
$3.62
Change
-$0.04 (-1.09%)
Updated
Nov 2 closing price
Capitalization
253.37M
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs BCYC

ARCT vs BCYC Comparison Chart in %
View a ticker or compare two or three
VS
ARCT vs. BCYC commentary
Nov 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and BCYC is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARCT with price predictions
Nov 02, 2026

ARCT in +8.19% Uptrend, rising for three consecutive days on October 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 55 cases where ARCT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 72 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for ARCT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ARCT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.570) is normal, around the industry mean (3.104). P/E Ratio (-2.850) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for BCYC with price predictions
Nov 02, 2026

Aroon Indicator for BCYC shows an upward move is likely

BCYC's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator showed a similar pattern. In 120 of the 137 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCYC's RSI Oscillator exited the oversold zone, 37 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BCYC as a result. In 62 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for BCYC just turned positive on October 22, 2026. Looking at past instances where BCYC's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.

Following a +6.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 188 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 48 cases where BCYC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

BCYC moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

BCYC broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.497) is normal, around the industry mean (3.104). P/E Ratio (-1.326) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARCT vs BCYC: Fundamental Ratings
ARCT
BCYC
OUTLOOK RATING
1..100
2314
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
3873
P/E GROWTH RATING
1..100
9328
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (34) in the Pharmaceuticals Major industry is in the same range as BCYC (35) in the null industry. This means that ARCT’s stock grew similarly to BCYC’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that ARCT’s stock grew similarly to BCYC’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for BCYC (73) in the null industry. This means that ARCT’s stock grew somewhat faster than BCYC’s over the last 12 months.

BCYC's P/E Growth Rating (28) in the null industry is somewhat better than the same rating for ARCT (93) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew somewhat faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTBCYC
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 03, 2026
Stock price -- (ARCT: $11.03 vs. BCYC: $3.66)
Brand notoriety: ARCT and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 213% vs. BCYC: 73%
Market capitalization -- ARCT: $269.73M vs. BCYC: $253.37M
ARCT [@Biotechnology] is valued at $269.73M. BCYC’s [@Biotechnology] market capitalization is $253.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $140.2B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 1 FA rating(s) are green while BCYC’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 1 green, 4 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARCT and BCYC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while BCYC’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 5 bearish.
  • BCYC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ARCT and BCYC are a bad buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а +12.09% price change this week, while BCYC (@Biotechnology) price change was +3.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.85%. For the same industry, the average monthly price growth was -13.09%, and the average quarterly price growth was -20.02%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2026.

BCYC is expected to report earnings on Mar 02, 2027.

Industries' Descriptions

@Biotechnology (-0.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARCT
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CRSP. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-13.96%
CRSP - ARCT
51%
Loosely correlated
-2.78%
EDIT - ARCT
50%
Loosely correlated
-3.75%
BCYC - ARCT
49%
Loosely correlated
-1.09%
AXON - ARCT
49%
Loosely correlated
-0.55%
SANA - ARCT
48%
Loosely correlated
-6.61%
More

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with PCVX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-1.09%
PCVX - BCYC
57%
Loosely correlated
-2.27%
ARCT - BCYC
50%
Loosely correlated
-13.96%
EDIT - BCYC
49%
Loosely correlated
-3.75%
RCKT - BCYC
49%
Loosely correlated
+1.23%
STOK - BCYC
48%
Loosely correlated
+0.72%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CSRE28.330.21
+0.75%
Cohen & Steers Real Estate Active ETF (CSRE)
FELC42.53-0.17
-0.40%
Fidelity Enhanced Large Cap Core ETF (FELC)
EPV18.39-0.25
-1.34%
ProShares UltraShort FTSE Europe (EPV)
AHLT29.35-0.63
-2.09%
American Beacon AHL Trend ETF (AHLT)
FMED31.54-0.87
-2.68%
Fidelity Disruptive Medicine ETF (FMED)